To compare the efficacy of topical 0.01% bimatoprost with topical 0.5% timolol maleate in glaucoma patients

Dr. A. Venkateswara Rao; Dr. S.P.V Sai Sindhuja

Volume : VIII, Issue : III, March - 2018

To compare the efficacy of topical 0.01% bimatoprost with topical 0.5% timolol maleate in glaucoma patients

Dr. A. Venkateswara Rao, Dr. S. P. V Sai Sindhuja

Abstract :

OBJECTIVE: To compare the safety and efficacy of Bimatoprost 0.01% ophthalmic solution with Timolol maleate 0.5% ophthalmic solution in the treatment of Primary open angle glaucoma.

MATERIALS AND METHODS: 50 Patients with POAG were included in a prospective randomized double blinded study.Patients were divided into two groups,25 patients each,Group A received Bimatoprost 0.01 % ophthalmic solution in the study eye once daily, in the evening and Group B recieved Timolol maleate 0.5% ophthalmic solution in the study eye twice daily, at 12 hour interval.In all these patients Intraocular pressure was recorded at base line(day 0) and treatment scheduled follow up visits – 2wks, 6wks, 3mths, 6mths .Primary adverse effects were monitored throughout the study.

RESULTS: In this study mean reduction of IOP at 2 wks, 6 wks, 12 wks, 24 wks were 6.96 mmHg (24.71%), 9.52 mmHg (33.80%), 10.76 mmHg (38.21%), 10.96 mmHg (38.92%) for Group A ( Bimatoprost group) and 4.08 mmHg (14.91%), 5.84 mmHg (21.34%), 6.96 mmHg (25.43%) and 7.2 mmHg (26.31%) for Group B (Timolol group) respectively.

CONCLUSION : Bimatoprost 0.01% ophthalmic solution was highly efficacious and well tolerated with minimal ocular side effects . It can be used as first line therapy to treat cases of POAG to reduce IOP. The only limitation for its use is regarding its cost. The topical Bimatoprost preparations are expensive when compared to the topical Timolol maleate.Considering the reduction in IOP, the modifiable factor for preventing the progression of optic nerve head damage Bimatoprost can be used to treat POAG patients.